agmatine and u-50488
agmatine has been researched along with u-50488 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Jain, S; Kolesnikov, Y; Pasternak, GW | 1 |
| Ding, Z; Gerber, K; Raffa, RB; Rawls, SM; Roth, C | 1 |
Other Studies
2 other study(ies) available for agmatine and u-50488
| Article | Year |
|---|---|
Modulation of opioid analgesia by agmatine.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Agmatine; Analgesia; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Synergism; Drug Tolerance; Gastrointestinal Transit; Injections, Intraventricular; Injections, Spinal; Male; Mice; Morphine; Pyrrolidines; Receptors, Opioid, kappa | 1996 |
Agmatine: identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Agmatine; Animals; Benzoxazines; Cannabinoids; Methamphetamine; Morpholines; Motor Activity; Naphthalenes; Planarians; Receptors, Opioid, kappa; Substance Withdrawal Syndrome | 2008 |